In May 2025, the FDA released draft guidance titled "Replacing Color Additives in Approved or Marketed Drug Products," addressing the process for modifying color additives in existing products. This guidance aims to streamline regulatory submissions for such changes, impacting manufacturers of diagnostic agents seeking to update formulations.
In January 2026, the FDA updated the Orange Book to enhance clarity on reference listed drugs (RLDs) and reference standards. These updates assist ANDA applicants in accurately identifying appropriate RLDs and reference standards, facilitating the approval process for generic diagnostic agents.
In January 2026, the Congressional Research Service published a report titled "Patent Listing in FDA’s Orange Book," providing an overview of the patent listing process and its implications for generic drug competition. This report offers valuable insights for manufacturers navigating patent landscapes in the diagnostic sector.
In February 2026, the FDA emphasized the importance of the one-time marketing status report required by the FDA Reauthorization Act of 2017 (FDARA). This report mandates that NDA and ANDA holders confirm the marketing status of their approved products, ensuring the accuracy of the Orange Book listings.
In March 2026, the FDA announced the availability of the latest Orange Book data files, providing updated information on approved drug products, including therapeutic equivalence evaluations. These resources are essential for stakeholders in the diagnostic industry to stay informed about market dynamics and regulatory statuses.
